Stifel Financial Corp and Janus Henderson Group increased their holdings in Takeda Pharmaceutical while Oppenheimer reduced their position. Despite 5.9% drop over four weeks, Takeda's (TAK) stock is still considered as relatively undervalued and a lucrative option for income investors with a high dividend yield. Yet, the dividend yield can be deceitful, especially for US investors. Takeda has had promising progress with its new product updates, strategic alliances, and expansion of collaborations in oncology, contributing to overall growth. It also raised financial forecasts for FY2024 and reported robust earnings growth, surpassing expectations. However, high short interest indicates possible bearish outlook. Takeda has a 15% CAGR over the last three years demonstrating profitability. Its largest shareholders are individual investors who hold 52%, while institutions own 46%. The company has announced a subsidiary merger and is increasing its dividend to ¥98.00. Recent deals with AC Immune, Lupin and Sun Pharma as well as launching an employee incentive plan and stock compensation scheme have been made.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Sat, 14 Dec 2024 09:16:26 GMT -
Rating 6
- Innovation 4
- Information 7
- Rumor -5
